Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,398 shares of the biopharmaceutical company’s stock after purchasing an additional 361 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Gilead Sciences were worth $397,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GILD. Waldron Private Wealth LLC boosted its position in Gilead Sciences by 2.7% in the 1st quarter. Waldron Private Wealth LLC now owns 8,949 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 233 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Gilead Sciences by 7.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 2,189,433 shares of the biopharmaceutical company’s stock valued at $130,162,000 after buying an additional 160,481 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its position in Gilead Sciences by 8.9% in the 1st quarter. Gladstone Institutional Advisory LLC now owns 12,835 shares of the biopharmaceutical company’s stock valued at $763,000 after buying an additional 1,050 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Gilead Sciences by 18.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 36,186 shares of the biopharmaceutical company’s stock valued at $2,151,000 after buying an additional 5,598 shares during the last quarter. Finally, Banque Pictet & Cie SA boosted its position in Gilead Sciences by 76.7% in the 1st quarter. Banque Pictet & Cie SA now owns 77,315 shares of the biopharmaceutical company’s stock valued at $4,596,000 after buying an additional 33,558 shares during the last quarter. 78.58% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $85.42 on Thursday. The firm’s 50 day moving average is $71.28 and its two-hundred day moving average is $65.64. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $86.15. The firm has a market capitalization of $107.14 billion, a P/E ratio of 32.23, a PEG ratio of 0.77 and a beta of 0.42. The company has a current ratio of 1.30, a quick ratio of 1.16 and a debt-to-equity ratio of 1.14.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be paid a $0.73 dividend. The ex-dividend date is Wednesday, December 14th. This represents a $2.92 annualized dividend and a dividend yield of 3.42%. Gilead Sciences’s payout ratio is currently 110.19%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. Jefferies Financial Group upped their price objective on shares of Gilead Sciences from $78.00 to $86.00 and gave the company a “buy” rating in a research report on Friday, October 28th. Piper Sandler raised shares of Gilead Sciences from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $79.00 to $96.00 in a research report on Friday, October 28th. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $79.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, October 28th. Barclays raised shares of Gilead Sciences from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $60.00 to $76.00 in a research report on Monday, October 31st. Finally, Cowen increased their price target on shares of Gilead Sciences from $80.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 8th. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $82.70.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CAO Diane E. Wilfong sold 6,416 shares of the firm’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total value of $535,736.00. Following the sale, the chief accounting officer now owns 28,333 shares in the company, valued at $2,365,805.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Diane E. Wilfong sold 6,416 shares of the firm’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total transaction of $535,736.00. Following the transaction, the chief accounting officer now owns 28,333 shares in the company, valued at $2,365,805.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Diane E. Wilfong sold 16,255 shares of the firm’s stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $79.25, for a total transaction of $1,288,208.75. Following the transaction, the chief accounting officer now owns 28,333 shares in the company, valued at approximately $2,245,390.25. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.